Aligos Historical Balance Sheet

ALGS Stock

USD 17.68 0.35 2.02%

Trend analysis of Aligos Therapeutics balance sheet accounts such as Short Long Term Debt Total of 10.6 M, Other Current Liabilities of 12.3 M or Total Current Liabilities of 27.1 M provides information on Aligos Therapeutics' total assets, liabilities, and equity, which is the actual value of Aligos Therapeutics to its prevalent stockholders. By breaking down trends over time using Aligos Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Aligos Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aligos Therapeutics is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aligos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Aligos Stock please use our How to Invest in Aligos Therapeutics guide.

About Aligos Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Aligos Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Aligos Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Aligos Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Aligos currently owns. An asset can also be divided into two categories, current and non-current.

Aligos Therapeutics Balance Sheet Chart

At this time, Aligos Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 51.1 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 27.1 M in 2025.

Total Assets Short Long Term Debt Total Cash And Short Term Investments Short Term Investments Liabilities And Stockholders Equity Other Current Assets

Add Fundamental

Total Assets

Total assets refers to the total amount of Aligos Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Aligos Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Aligos Therapeutics balance sheet. This account contains Aligos Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Aligos Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Short Term Investments

Short Term Investments is an item under the current assets section of Aligos Therapeutics balance sheet. It contains any investments Aligos Therapeutics undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Aligos Therapeutics can easily liquidate in the marketplace.

Liabilities And Stockholders Equity

The total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation.

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Most accounts from Aligos Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Aligos Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aligos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Aligos Stock please use our How to Invest in Aligos Therapeutics guide.At this time, Aligos Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 51.1 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 27.1 M in 2025.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	12.6M	11.1M	10.0M	10.6M
Total Assets	146.7M	151.5M	174.3M	193.1M

Short Long Term Debt Total Total Assets

Aligos Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		-0.35	0.82	0.87	0.91	0.35	0.9	-0.31	0.45	-0.97	-0.61	0.22	0.97	0.3	-0.39	-0.21	0.99	0.77	-0.8	-0.7	-0.35	0.84	0.73	-0.63	0.91	0.5
Short Long Term Debt Total	-0.35		-0.62	-0.5	-0.46	0.28	-0.49	0.96	0.41	0.47	0.82	-0.09	-0.52	0.59	0.0	0.91	-0.4	-0.35	0.74	0.57	1.0	-0.36	-0.81	0.59	-0.46	-0.68
Other Current Liab	0.82	-0.62		0.95	0.9	-0.14	0.91	-0.69	0.23	-0.89	-0.9	0.14	0.91	0.07	-0.15	-0.46	0.81	0.81	-0.93	-0.88	-0.62	0.93	0.94	-0.82	0.9	0.87
Total Current Liabilities	0.87	-0.5	0.95		0.91	-0.01	0.91	-0.55	0.46	-0.9	-0.85	0.41	0.9	0.19	-0.34	-0.27	0.85	0.94	-0.86	-0.85	-0.5	0.96	0.9	-0.77	0.91	0.82
Total Stockholder Equity	0.91	-0.46	0.9	0.91		0.07	1.0	-0.47	0.38	-0.93	-0.72	0.17	0.93	0.05	-0.45	-0.26	0.92	0.84	-0.79	-0.93	-0.46	0.88	0.84	-0.89	1.0	0.62
Other Liab	0.35	0.28	-0.14	-0.01	0.07		0.06	0.42	0.47	-0.26	0.29	0.16	0.24	0.26	-0.55	0.24	0.38	-0.06	0.09	0.25	0.28	-0.12	-0.23	0.31	0.07	-0.45
Net Tangible Assets	0.9	-0.49	0.91	0.91	1.0	0.06		-0.5	0.35	-0.93	-0.74	0.15	0.93	0.02	-0.43	-0.29	0.92	0.83	-0.81	-0.93	-0.49	0.87	0.86	-0.89	1.0	0.64
Property Plant And Equipment Net	-0.31	0.96	-0.69	-0.55	-0.47	0.42	-0.5		0.37	0.46	0.88	-0.04	-0.51	0.53	-0.09	0.88	-0.35	-0.39	0.76	0.62	0.96	-0.44	-0.83	0.64	-0.47	-0.8
Current Deferred Revenue	0.45	0.41	0.23	0.46	0.38	0.47	0.35	0.37		-0.36	-0.03	0.63	0.32	0.55	-0.68	0.64	0.41	0.6	-0.01	-0.22	0.41	0.45	0.06	-0.12	0.38	0.08
Net Debt	-0.97	0.47	-0.89	-0.9	-0.93	-0.26	-0.93	0.46	-0.36		0.73	-0.15	-0.99	-0.19	0.34	0.36	-0.98	-0.75	0.88	0.76	0.47	-0.85	-0.82	0.69	-0.93	-0.59
Retained Earnings	-0.61	0.82	-0.9	-0.85	-0.72	0.29	-0.74	0.88	-0.03	0.73		-0.28	-0.75	0.18	0.09	0.67	-0.61	-0.73	0.91	0.79	0.82	-0.77	-0.96	0.75	-0.72	-0.92
Accounts Payable	0.22	-0.09	0.14	0.41	0.17	0.16	0.15	-0.04	0.63	-0.15	-0.28		0.13	0.13	-0.57	0.22	0.2	0.62	-0.08	-0.17	-0.09	0.3	0.25	-0.11	0.17	0.29
Cash	0.97	-0.52	0.91	0.9	0.93	0.24	0.93	-0.51	0.32	-0.99	-0.75	0.13		0.16	-0.31	-0.4	0.97	0.74	-0.9	-0.77	-0.52	0.85	0.84	-0.7	0.93	0.63
Non Current Assets Total	0.3	0.59	0.07	0.19	0.05	0.26	0.02	0.53	0.55	-0.19	0.18	0.13	0.16		0.18	0.53	0.2	0.2	-0.04	0.2	0.59	0.36	-0.17	0.3	0.05	-0.01
Non Currrent Assets Other	-0.39	0.0	-0.15	-0.34	-0.45	-0.55	-0.43	-0.09	-0.68	0.34	0.09	-0.57	-0.31	0.18		-0.28	-0.45	-0.48	-0.01	0.38	0.0	-0.18	-0.17	0.36	-0.45	0.07
Other Assets	-0.21	0.91	-0.46	-0.27	-0.26	0.24	-0.29	0.88	0.64	0.36	0.67	0.22	-0.4	0.53	-0.28		-0.26	-0.04	0.68	0.32	0.91	-0.16	-0.63	0.35	-0.26	-0.49
Cash And Short Term Investments	0.99	-0.4	0.81	0.85	0.92	0.38	0.92	-0.35	0.41	-0.98	-0.61	0.2	0.97	0.2	-0.45	-0.26		0.74	-0.79	-0.72	-0.4	0.8	0.74	-0.66	0.92	0.48
Common Stock Shares Outstanding	0.77	-0.35	0.81	0.94	0.84	-0.06	0.83	-0.39	0.6	-0.75	-0.73	0.62	0.74	0.2	-0.48	-0.04	0.74		-0.66	-0.82	-0.35	0.91	0.79	-0.76	0.84	0.73
Short Term Investments	-0.8	0.74	-0.93	-0.86	-0.79	0.09	-0.81	0.76	-0.01	0.88	0.91	-0.08	-0.9	-0.04	-0.01	0.68	-0.79	-0.66		0.73	0.74	-0.82	-0.93	0.67	-0.79	-0.82
Non Current Liabilities Total	-0.7	0.57	-0.88	-0.85	-0.93	0.25	-0.93	0.62	-0.22	0.76	0.79	-0.17	-0.77	0.2	0.38	0.32	-0.72	-0.82	0.73		0.57	-0.82	-0.88	0.99	-0.93	-0.72
Capital Lease Obligations	-0.35	1.0	-0.62	-0.5	-0.46	0.28	-0.49	0.96	0.41	0.47	0.82	-0.09	-0.52	0.59	0.0	0.91	-0.4	-0.35	0.74	0.57		-0.36	-0.81	0.59	-0.46	-0.68
Other Current Assets	0.84	-0.36	0.93	0.96	0.88	-0.12	0.87	-0.44	0.45	-0.85	-0.77	0.3	0.85	0.36	-0.18	-0.16	0.8	0.91	-0.82	-0.82	-0.36		0.83	-0.74	0.88	0.81
Other Stockholder Equity	0.73	-0.81	0.94	0.9	0.84	-0.23	0.86	-0.83	0.06	-0.82	-0.96	0.25	0.84	-0.17	-0.17	-0.63	0.74	0.79	-0.93	-0.88	-0.81	0.83		-0.85	0.84	0.87
Total Liab	-0.63	0.59	-0.82	-0.77	-0.89	0.31	-0.89	0.64	-0.12	0.69	0.75	-0.11	-0.7	0.3	0.36	0.35	-0.66	-0.76	0.67	0.99	0.59	-0.74	-0.85		-0.89	-0.67
Net Invested Capital	0.91	-0.46	0.9	0.91	1.0	0.07	1.0	-0.47	0.38	-0.93	-0.72	0.17	0.93	0.05	-0.45	-0.26	0.92	0.84	-0.79	-0.93	-0.46	0.88	0.84	-0.89		0.62
Property Plant And Equipment Gross	0.5	-0.68	0.87	0.82	0.62	-0.45	0.64	-0.8	0.08	-0.59	-0.92	0.29	0.63	-0.01	0.07	-0.49	0.48	0.73	-0.82	-0.72	-0.68	0.81	0.87	-0.67	0.62

Click cells to compare fundamentals

Aligos Therapeutics Account Relationship Matchups

Aligos Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	265.3M	235.4M	146.7M	151.5M	174.3M	193.1M
Short Long Term Debt Total	13.0M	14.5M	12.6M	11.1M	10.0M	10.6M
Other Current Liab	14.1M	22.5M	12.9M	16.8M	19.4M	12.3M
Total Current Liabilities	30.3M	39.0M	33.1M	23.9M	27.5M	27.1M
Total Stockholder Equity	220.0M	184.7M	103.9M	92.1M	105.9M	95.7M
Other Liab	3.6M	4.5M	133K	233K	209.7K	199.2K
Net Tangible Assets	(64.9M)	220.0M	184.7M	103.9M	119.5M	94.6M
Property Plant And Equipment Net	14.9M	15.0M	12.5M	9.8M	8.8M	11.1M
Current Deferred Revenue	7.9M	7.6M	9.2M	1.3M	1.2M	1.1M
Net Debt	(207.4M)	(172.4M)	(68.8M)	(124.6M)	(112.1M)	(117.7M)
Retained Earnings	(174.7M)	(303.1M)	(399.1M)	(486.8M)	(438.1M)	(416.2M)
Accounts Payable	3.3M	3.0M	4.7M	2.5M	2.9M	3.7M
Cash	220.4M	186.8M	81.3M	135.7M	156.1M	131.6M
Non Current Assets Total	15.3M	30.9M	13.1M	10.4M	9.4M	14.9M
Non Currrent Assets Other	(3.3M)	866K	(2.5M)	625K	562.5K	590.6K
Other Assets	7.3K	866K	634K	(2.4M)	(2.1M)	(2.0M)
Cash And Short Term Investments	243.5M	190.7M	125.8M	135.7M	156.1M	165.8M
Common Stock Shares Outstanding	34.2M	39.9M	42.7M	24.9M	28.6M	33.9M
Short Term Investments	23.1M	3.9M	44.5M	(70K)	(63K)	(59.9K)
Liabilities And Stockholders Equity	265.3M	235.4M	146.7M	151.5M	174.3M	193.1M
Non Current Liabilities Total	15.0M	11.7M	9.7M	35.5M	32.0M	51.1M
Capital Lease Obligations	13.0M	14.5M	12.6M	11.1M	10.0M	10.6M
Other Current Assets	6.5M	13.7M	7.7M	5.4M	6.2M	6.7M
Other Stockholder Equity	395.0M	487.3M	502.6M	578.3M	665.1M	698.3M
Total Liab	45.3M	50.6M	42.8M	59.4M	53.5M	70.8M
Net Invested Capital	220.0M	184.7M	103.9M	92.1M	105.9M	95.7M
Property Plant And Equipment Gross	14.9M	22.2M	22.1M	20.6M	23.7M	20.4M
Total Current Assets	250.0M	204.4M	133.5M	141.1M	162.2M	172.6M
Accumulated Other Comprehensive Income	(188K)	452K	401K	545K	626.8K	658.1K
Net Working Capital	219.7M	165.5M	100.4M	117.2M	134.8M	145.6M
Short Term Debt	5.0M	5.8M	6.3M	10.4M	11.9M	12.5M
Property Plant Equipment	16.1M	14.9M	15.0M	4.8M	4.3M	4.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aligos Stock Analysis

When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aligos Historical Balance Sheet

About Aligos Balance Sheet Analysis

Aligos Therapeutics Balance Sheet Chart

Total Assets

Cash And Short Term Investments

Short Term Investments

Liabilities And Stockholders Equity

Other Current Assets

Aligos Therapeutics balance sheet Correlations

Aligos Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aligos Therapeutics balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Aligos Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Net Tangible Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Total Liab	+ 0.99	Non Current Liabilities Total

Cash	- 0.99	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Net Debt	- 0.97	Total Assets
Other Stockholder Equity	- 0.96	Retained Earnings
Net Invested Capital	- 0.93	Non Current Liabilities Total
Other Stockholder Equity	- 0.93	Short Term Investments